Most PDACs harbor oncogenic KRAS mutations and elevated MYC signaling leading to dysregulation of global transcription and proliferation (7, 8), potentially sensitizing cancer cells to therapeutic targeting with transcriptional inhibitors. The gene discussed is KRAS; the disease is cancer.